{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262562","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.562230+00:00","generated_at":"2026-05-17T00:51:34.960536+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0","bullets":["Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.","Acquired VISTA-inhibiting mAb TBS-2025 via Kineta merger (June 2025); planning Phase 2 in mutNPM1 AML.","Deferred development of IFx-3.0 mRNA candidate pending IFx-2.0 Phase 3 data; resources shifted to TBS-2025.","Filed unaudited pro forma financials reflecting Kintara (Oct 2024) and Kineta (June 2025) mergers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262562","json":"https://secwatch.observer/filing/0001193125-25-262562.json","markdown":"https://secwatch.observer/filing/0001193125-25-262562.md","text":"https://secwatch.observer/filing/0001193125-25-262562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/0001193125-25-262562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/d73851d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:51:34.960536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}